Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

553
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
553
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

660
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
660
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

229
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
229
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longevity and Volume Expansion of Hyaluronic Acid Dermal Fillers: A Cross-sectional 3-dimensional Magnetic Resonance Imaging Study.

Plastic and reconstructive surgery. Global open·2026
Same author

Computer-aided diagnosis of eyelid skin tumours: new observations.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Contours and Confusions: A Review of Malar Mounds, Malar Edema, and Festoons.

The Journal of craniofacial surgery·2026
Same author

Combined Festoon Excision With Transmalar Lower Eyelid Blepharoplasty.

Plastic and reconstructive surgery. Global open·2026
Same author

Orbital solitary fibrous tumour invading the levator palpebrae and superior rectus muscle complex.

Orbit (Amsterdam, Netherlands)·2026
Same author

The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.

Reviews in endocrine & metabolic disorders·2026

Related Experiment Video

Updated: Sep 7, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

329

Rituximab for thyroid-associated ophthalmopathy.

Swan Kang1, Shirin Hamed Azzam1, Neda Minakaran2

  • 1Moorfields Eye Hospital NHS Foundation Trust, London, UK.

The Cochrane Database of Systematic Reviews
|June 16, 2022
PubMed
Summary

Rituximab (RTX) shows insufficient evidence for treating thyroid-associated ophthalmopathy (TAO). More multi-center studies are needed to determine the efficacy and safety of RTX for active TAO, a condition impacting quality of life.

More Related Videos

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue
09:42

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

Published on: June 7, 2017

11.6K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.0K

Related Experiment Videos

Last Updated: Sep 7, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

329
A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue
09:42

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

Published on: June 7, 2017

11.6K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.0K

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Thyroid-associated ophthalmopathy (TAO) is a common extrathyroidal manifestation of Graves' disease, significantly impacting patient quality of life.
  • Rituximab (RTX), a monoclonal antibody targeting CD20+ B-lymphocytes, has shown preliminary potential in reducing TAO inflammation and proptosis.

Purpose of the Study:

  • To assess the efficacy and safety of Rituximab (RTX) for treating active thyroid-associated ophthalmopathy (TAO).
  • This review updates previous findings on RTX for TAO, evaluating its impact on clinical outcomes and adverse effects.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) comparing RTX with placebo or glucocorticoids for active TAO.
  • Searched multiple databases (Cochrane CENTRAL, MEDLINE, Embase, LILACS, clinicaltrials.gov) up to February 2022.
  • Key outcomes included clinical activity score (CAS), NOSPECS severity, proptosis, palpebral aperture, motility, quality of life, and adverse events.

Main Results:

  • Two studies met inclusion criteria; one compared RTX to intravenous methylprednisolone (IVMP), the other to placebo.
  • Low-certainty evidence suggested RTX may improve CAS compared to IVMP, but adverse events were more frequent with RTX.
  • Very low-certainty evidence from the placebo-controlled study indicated more adverse effects in the RTX group, with unclear benefits on other outcomes.

Conclusions:

  • Current evidence is insufficient to support the use of Rituximab (RTX) for treating thyroid-associated ophthalmopathy (TAO).
  • Further multi-center trials are necessary to adequately evaluate the efficacy and safety of RTX in patients with active TAO.